255
Participants
Start Date
March 31, 2009
Primary Completion Date
April 30, 2010
Study Completion Date
April 30, 2010
exenatide and sitagliptin
exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
exenatide and placebo
exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
Research Site, Buenos Aires
Research Site, Morón
Research Site, Adelaide
Research Site, Geelong
Research Site, Melbourne
Research Site, Aschaffenburg
Research Site, Aßlar
Research Site, Beckum-Neubeckum
Research Site, Berlin
Research Site, Bosenheim
Research Site, Essen
Research Site, Falkensee
Research Site, Furth im Wald
Research Site, Grevenbroich
Research Site, Hohenmölsen
Research Site, Leipzig
Research Site, Neuwied
Research Site, Othmarschen
Research Site, Pohlheim
Research Site, Speyer
Research Site, Athens
Research Site, Thessaloniki
Research Site, Ahmedabad
Research Site, Bangalore
Research Site, Coimbatore
Research Site, Indore
Research Site, Jaipur
Research Site, Coatzacoalcos
Research Site, Guadalajara
Research Site, Mérida
Research Site, Monterrey
Research Site, Tampico
Research Site, Daegu
Research Site, Gwangju
Research Site, Seoul
Research Site, Ulsan
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY